ADOCIA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.25 EUR | -3.62% |
|
-6.67% | -28.51% |
| Jun. 04 | Adocia appoints Director of Operations | CF |
| Jun. 03 | Adocia Announces Appointment of Mathieu-William Gilbert as Chief Operating Officer | CI |
| Sales 2024 * | 50M 53.73M | Sales 2025 * | 86M 92.41M | Capitalization | 126M 135M |
|---|---|---|---|---|---|
| Net income 2024 * | 26M 27.94M | Net income 2025 * | 40M 42.98M | EV / Sales 2024 * | 2.07 x |
| Net cash position 2024 * | 22.5M 24.18M | Net cash position 2025 * | 62.3M 66.95M | EV / Sales 2025 * | 0.74 x |
| P/E ratio 2024 * |
2.3
x | P/E ratio 2025 * |
1.53
x | Employees | 78 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.51% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -3.39% | ||
| 1 week | -6.45% | ||
| Current month | -8.11% | ||
| 1 month | -4.17% | ||
| 3 months | -11.08% | ||
| 6 months | +0.98% | ||
| Current year | -28.34% |
1 week
8.25
9.44
1 month
8.259.99
Current year
7.8912.40
1 year
3.5916.16
3 years
2.7516.16
5 years
2.7522.60
10 years
2.7594.24
| Managers | Title | Age | Since |
|---|---|---|---|
Olivier Soula
FOU | Founder | 53 | 05-12-15 |
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director of Finance/CFO | - | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director/Board Member | 67 | 21-05-20 | |
| Director/Board Member | 58 | 13-06-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 8.25 | -3.62% | 60 880 |
| 24-06-07 | 8.56 | +0.12% | 58,745 |
| 24-06-06 | 8.55 | -0.58% | 36,746 |
| 24-06-05 | 8.6 | -0.23% | 70,473 |
| 24-06-04 | 8.62 | -2.49% | 182,385 |
Real-time Euronext Paris, June 10, 2024 at 07:43 am EDT
More quotes
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.
At the end of 2023, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Calendar
2024-06-13
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.56
EUR
Average target price
9.7
EUR
Spread / Average Target
+13.32%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.34% | 136M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +0.73% | 22.78B | |
| -10.72% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- ADOC Stock
